Quest Diagnostics Finds High Tick-Borne Disease Co-Exposure
Secaucus, New Jersey, U.S., September 21, 2026 Quest Diagnostics and researchers from the University of North Carolina at Chapel...
Diagnostic Testing
Advertisement
Adaptive Highlights Updated NCCN MRD Guidance in Multiple Myeloma
SEATTLE, Wash. — September 17, 2026 Adaptive Biotechnologies highlighted updates to the National Comprehensive Cancer Network (NCCN) Guidelines for...
Intelligent Bio Solutions Reports 98.2% Accuracy in Drug Testing
NEW YORK, September 2, 2026 Intelligent Bio Solutions Inc. has reported strong performance results for its Intelligent Fingerprinting Drug...
Natera Partners With Susan G. Komen to Advance Breast Cancer Awareness
Austin, Texas – August 28, 2026 Natera, Inc. announced a new national partnership with Susan G. Komen to accelerate...
Roche Wins FDA Clearance for Elecsys pTau217 Test
INDIANAPOLIS, U.S., Aug 28, 2026 Roche has received U.S. FDA clearance for Elecsys® Phospho-Tau (217P) Plasma (pTau217), a blood-based...
Advertisements
Quest Diagnostics Adds Roche pTau217 Blood Test to AD Portfolio
Secaucus, New Jersey, August 24, 2026 Quest Diagnostics announced new developments in its Quest AD-Detect® blood-testing portfolio, expanding access...
Nuvation Bio Gains FDA Fast Track for Safusidenib
New York, New York, August 20, 2026 Nuvation Bio Inc. has announced that the U.S. Food and Drug Administration...
FDA Authorizes Aletta Robotic Blood Draw Device
Silver Spring, Maryland, August 19, 2026 The U.S. Food and Drug Administration (FDA) has authorized Aletta, a first-of-its-kind standalone...
QIAGEN Gains FDA Clearance for Bloodstream Infection Testing
Germantown, Maryland, and Venlo, Netherlands, August, 10, 2026 QIAGEN has received U.S. Food and Drug Administration (FDA) clearance for...
Elicio Therapeutics Activates Phase 1 Study of ELI-002 7P
Boston, Aug. 10, 2026 Elicio Therapeutics, Inc. announced the activation of an investigator-initiated Phase 1 clinical study evaluating its...
Advertisement
